Molecularly targeted therapies for nonmelanoma skin cancers

Authors


  • Funding: None.

    Conflicts of interest: No conflicts of interest for Dr. Colegio or Lucinda.

Correspondence

Oscar R. Colegio, md, phd

Transplant Dermatology Clinic

Yale School of Medicine

333 Cedar Street, LMP 5040

New Haven, CT 06520-8059,USA

E-mail: oscar.colegio@yale.edu

Abstract

Over the past two decades, advances in the fields of cancer genetics and molecular biology have elucidated molecular pathways that cause numerous cutaneous malignancies. This in turn has spurred the rational design of molecularly targeted therapies. In this review, we discuss the molecular pathways critical to the development of nonmelanoma skin cancers and the novel pharmacologic agents that target them. Included is a review of vismodegib for basal cell carcinoma, cetuximab for squamous cell carcinomas, imatinib for dermatofibrosarcoma protuberans, and sirolimus for Kaposi's sarcoma.

Ancillary